

| | |
|--------------|---|
| Title | Pulmonary Arterial Pressure Management Based on Oral Medicine for Pediatric Living Donor Liver Transplant With Portopulmonary Hypertension |
| Author(s) | Ueno, T.; Hiwatashi, S.; Saka, R. et al. |
| Citation | Transplantation Proceedings. 2018, 50(9), p. 2614-2618 |
| Version Type | AM |
| URL | https://hdl.handle.net/11094/97128 |
| rights | © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Note | |

Osaka University Knowledge Archive : OUKA

<https://ir.library.osaka-u.ac.jp/>

Osaka University

Figure captions:

Fig. 1 Clinical course of case 4 : A) pre LDLT course showed mPAP and events before LDLT. Horizontal axis showed months from first episode of PH crisis. B) post LDLT course showed mPAP and events after LDLT. LDLT: living donor liver transplant; mPAP: mean pulmonary artery pressure; NO: nitrate oxide; OP: operation; PH: portal hypertension; P-S : port-systemic

Fig. 2 Pre transplant treatment for pulmonary hypertension: A) PH medications showed pre LDLT treatment for PH. B) mean PAP showed mean PAP changes between pretreatment of PH and pre LDLT. ERA: endothelin receptor antagonists; iv: intravenous; LDLT: living donor liver transplant; PAP: pulmonary artery pressure; PDE5: phosphodiesterase 5; PGI2: prostacyclin; PH: portal hypertension; Tx : treatment